Known patch test allergens for Dermatitis

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Massachusetts Chan Medical School, Worcester, MA
Dermatitis+5 More
Known patch test allergens - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study how anti-inflammatory skin therapies work to understand how they can be used to treat skin conditions. The treatment being studied, known patch test allergens, is used to treat Dermatitis. This treatment involves immunotherapy, and has previously been approved by the FDA for a different condition. No patients in this trial will receive a placebo.

Eligible Conditions

  • Dermatitis
  • Allergic Contact Dermatitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Dermatitis

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 5 years

Up to 5 years
Correlation of protein biomarkers collected by microneedles
To collect and evaluate single-cell multiomics data (RNAseq, CITEseq, TCRseq)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Dermatitis

Trial Design

2 Treatment Groups

Contact Allergen with Immunomodulator Pre-Treatment
1 of 2
Baseline Contact Allergen
1 of 2
Experimental Treatment

45 Total Participants · 2 Treatment Groups

Primary Treatment: Known patch test allergens · No Placebo Group · Phase 2 & 3

Contact Allergen with Immunomodulator Pre-TreatmentExperimental Group · 13 Interventions: Suction blistering, Squaric Acid Dibutyl Ester, Fluticasone Propionate, Guselkumab, Sarilumab, Known patch test allergens, Triamcinolone Acetonide, Adalimumab, Microneedle, Dupilumab, Canakinumab, Betamethasone Valerate, Ustekinumab · Intervention Types: Device, Drug, Drug, Drug, Drug, Other, Drug, Drug, Device, Drug, Drug, Drug, Drug
Baseline Contact AllergenExperimental Group · 4 Interventions: Suction blistering, Squaric Acid Dibutyl Ester, Known patch test allergens, Microneedle · Intervention Types: Device, Drug, Other, Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Squaric Acid Dibutyl Ester
2017
Completed Phase 1
~40
Fluticasone Propionate
2011
Completed Phase 4
~3500
Guselkumab
2015
Completed Phase 4
~5280
Sarilumab
2020
Completed Phase 3
~5860
Triamcinolone Acetonide
2017
Completed Phase 4
~3470
Adalimumab
2013
Completed Phase 4
~7100
Microneedle
2008
Completed Phase 3
~150
Dupilumab
2017
Completed Phase 3
~12150
Canakinumab
2011
Completed Phase 3
~3290
Betamethasone Valerate
2012
Completed Phase 3
~60
Ustekinumab
2013
Completed Phase 4
~4230

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
Closest Location: University of Massachusetts Chan Medical School · Worcester, MA
Photo of massachusetts 1Photo of massachusetts 2Photo of massachusetts 3
2022First Recorded Clinical Trial
1 TrialsResearching Dermatitis
1 CompletedClinical Trials

Who is running the clinical trial?

John HarrisLead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
John Harris, MD, PhDPrincipal InvestigatorUniversity of Massachusetts Chan Medical School

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a skin condition that is not a skin disease.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.